Alphamab Oncology

English 中文簡體中文繁體

English 中文簡體中文繁體

Alphamab Oncology Reports Full Year 2022 Financial Results and Business Highlights

we will seize the opportunity of commercialization of KN046 to establish an efficient commercial system and accelerate the delivery of innovative products to more patients
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

JSKN003-102 trial and ongoing JSKN003-101 complement with each other, laying the foundation for the global development of JSKN003
Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023

Late-Breaking Research: Experimental and Molecular Therapeutics

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable

Our Vision : To become a fully integrated global leading biopharmaceutical company

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

Learn More

Proprietary Platforms
Innovative Pipeline
Biologics Manufacturing

WORLD-CLASS BISPECIFIC AND MIX-MAB PLATFORMS

In complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. At Alphamab Oncology, we have developed two proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

Learn More

INNOVATIVE PIPELINE WITH SIGNIFICANT POTENTIAL AND MITIGATED DEVELOPMENT RISK

Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

Learn More

STATE OF ART cGMP MANUFACTURING WITH A SOLID TRACK RECORD

The production of biologics, such as antibody drugs, is a complex, lengthy and costly process. We have established our own cGMP production facilities with strong in house expertise to address the manufacturing issues.

Learn More

奶头被医生摸得受不了_暖暖韩国日本大全免费_gogo亚洲肉体艺术无码_欧美高清大屁股xxxxx